In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

Up 42% in a year, not including dividends, here’s why ResMed Inc (ASX: RMD) shares can keep charging ahead in 2025.

Jonathan Van Ness is getting candid about his weight loss journey. In a vulnerable new video posted to TikTok this week, the ...

Biologic Pharmamedical invites wellness brands, MLMs, and co-manufacturers to explore how these patented technologies can revolutionize their product lines. From formulation to marketing, Biologic ...

You’ve likely heard the term GLP1 when it comes to medications. These are the diabetes treatments now being used as a tool for weight loss. While the results can be dramatic, many are wondering if ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

At 53, she's not only lost over 50 pounds but has successfully maintained her weight loss for over a year. Here's her ...

Ozempic is a brand name semaglutide, a medication used to treat type 2 diabetes. It’s also used as an off-label use for weight loss. Wegovy is another brand name with the same a ...

LA GLP1-RAs have shown at least equal reduction ... of these antibodies result in significant decrease in efficacy of the medication class. LA GLP1-RAs in studies to date appear to be a cost ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...